TB-500 dosage, as it appears in the research record

TB-500 Dosage in the Research Literature

TB-500 dosage figures in the literature are research-context figures, not protocols. They describe what was administered to animals or to volunteers in a controlled study, and almost all of them are for full-length thymosin beta-4, not the heptapeptide. Animal studies dosed the protein across a wide range: roughly 6–12 mg/kg in cardiac and neurological rodent models; 2, 12, or 18 mg/kg intraperitoneally in the embolic-stroke dose-response study, where the optimal dose was modeled near 3.75 mg/kg ^[4]; and 150 µg twice weekly intraperitoneally for 6 months in the mdx muscular-dystrophy study ^[9].

Picogram-to-nanogram amounts are bioactive in vitro — about 10 pg was active in keratinocyte migration assays, and nanomolar thymosin beta-4 stimulates hair-follicle stem cells ^[3]. The non-clinical "loading then maintenance" protocols circulated in athletic and peptide-research communities are not derived from controlled human trials and have no published clinical validation ^[13]. The stroke dose-response is the clearest reason for caution: 18 mg/kg performed no better than 2 mg/kg, so escalating the dose is not supported by the data ^[4].

How much TB-500 should be taken per week during a loading phase?

Community "loading then maintenance" protocols are not derived from controlled human trials and have no published clinical validation ^[13]. Animal studies dosed full-length thymosin beta-4 by body weight in milligram-per-kilogram ranges ^[4], which cannot be translated into a human weekly amount.

TB-500 Half-Life and Pharmacokinetics

No validated human pharmacokinetic half-life exists for the TB-500 heptapeptide ^[13]. The closest human data come from the full-length protein: in a randomized, placebo-controlled Phase 1 study, intravenous synthetic thymosin beta-4 in 40 healthy volunteers showed dose-proportional pharmacokinetics, with half-life increasing as dose increased ^[6]. Anti-doping LC-MS work has characterized TB-500 and its metabolites in equine plasma and urine, but that work is built for detection, not for human pharmacokinetic modeling ^[13]. For the broader human clinical status of thymosin β4, the only completed human data are for the full-length protein.

What is the half-life of TB-500 and how often should it be dosed?

No validated human pharmacokinetic half-life exists for the TB-500 heptapeptide ^[13]. In the intravenous full-length thymosin beta-4 Phase 1 study, half-life increased with dose, i.e. the pharmacokinetics were dose-proportional ^[6]. There is no evidentiary basis for a fragment dosing frequency in humans.

Routes studied and material handling

Routes in the efficacy literature are dominated by what the researchers used, not by what circulates in communities. Intraperitoneal dosing predominated in rodent efficacy studies ^[4]. Intravenous dosing appeared in the human Phase 1 of full-length thymosin beta-4 and in some cardiac models ^[6]. Topical and ophthalmic routes were used in corneal and dermal wound work and in dry-eye trials of the clinical-grade formulation RGN-259 ^[3]. Subcutaneous and intramuscular routes are community research-use routes that are not drawn from controlled human efficacy trials ^[13].

How does subcutaneous vs intramuscular injection of TB-500 compare?

Rodent efficacy studies predominantly used intraperitoneal dosing ^[4]; subcutaneous and intramuscular are community research-use routes not validated in controlled human efficacy trials ^[13]. No comparative human data establish a difference between them for the fragment.

TB-500 is supplied as a lyophilized powder, reconstituted in bacteriostatic or sterile water and kept refrigerated. As a short acetylated peptide it is more chemically robust than the full-length protein, but it remains subject to proteolysis and freeze-thaw degradation, and the identity and purity of research-grade material are a recurring concern ^[13].